Intervening TNF- via PPAR γ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Wang, Yun Liang ^a   Liu, Li Juan ^a   Zhao, Wei Han ^a   Li, Jun Xiang ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COPTIS RHIZOME EXTRACT; GEGENQINLIAN DECOCTION; GLYCYRRHIZA EXTRACT; LIVER ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT MEDICINAL PRODUCT; PUERARIA EXTRACT; ROSIGLITAZONE; SCUTELLARIA BAICALENSIS EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DRUG MEGADOSE; FAT CONTENT; GENE EXPRESSION; HISTOPATHOLOGY; INFLAMMATION; LIPID METABOLISM; LOW DRUG DOSE; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84953859419     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/715638     Document Type: Article

References (46)

1. D.A. Sass, P. Chang, andK.B. Chopra,"Nonalcoholic fatty liver disease: a clinical review, "Digestive Diseases and Sciences, vol. 50, no. 1, pp. 171-180, 2005
2. M. Charlton,"Nonalcoholic fatty liver disease: a review of current understanding and future impact, "Clinical Gastroenterology and Hepatology, vol. 2, no. 12, pp. 1048-1058, 2004
3. R. Vuppalanchi and N. Chalasani,"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management, "Hepatology, vol. 49, no. 1, pp. 306-317, 2009
4. J. K. Dowman, J. W. Tomlinson, and P. N. Newsome,"Pathogenesis of non-Alcoholic fatty liver disease, "QJM, vol. 103, no. 2, Article ID hcp158, pp. 71-83, 2009
5. M. Enjoji, K. Yasutake, M. Kohjima, and M. Nakamuta,"Nutrition and nonalcoholic fatty liver disease: the significance of cholesterol, "International Journal of Hepatology, vol. 2012, Article ID 925807, 6 pages, 2012
6. C. Postic and J. Girard,"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice, "The Journal of Clinical Investigation, vol. 118, no. 3, pp. 829-838, 2008
7. M. Kugelmas, D. B. Hill, B. Vivian, L. Marsano, and C. J. McClain,"Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E, "Hepatology, vol. 38, no. 2, pp. 413-419, 2003
8. A. Gastaldelli, Y. Miyazaki, A. Mahankali et al.,"The effect of pioglitazone on the liver: role of adiponectin, "Diabetes Care, vol. 29, no. 10, pp. 2275-2281, 2006
9. C.-H. Zhang, G.-L. Xu, Y.-H. Liu et al.,"Anti-diabetic activities of Gegen Qinlian Decoction in high-fat diet combined with streptozotocin-induced diabetic rats and in 3T3-L1 adipocytes, "Phytomedicine, vol. 20, no. 3-4, pp. 221-229, 2013
10. X.-L. Tong, L.-H. Zhao, F.-M. Lian et al.,"Clinical observations on the dose-effect relationship of gegen qin lian decoction on 54 out-patients with type 2 diabetes, "Journal of Traditional Chinese Medicine, vol. 31, no. 1, pp. 56-59, 2011
11. S. Song, M. Qiu, Y. Chu et al.,"Berberine down-regulates cellular JNK and NF-B activation and this may result in an inhibition of HSV replication, "Antimicrobial Agents and Chemotherapy, 2014
12. Q. Wu, H. Ye, Y.-Z. Zhu, M. Guo, X.-X. He, and X.-B. Zheng,"Protective effect of baicalin against LPS-induced intestinal injury, "Zhongguo Zhongyao Zazhi, vol. 38, no. 17, pp. 2854-2858, 2013
13. X. Yang, J. Yang, and H. Zou,"Baicalin inhibits IL-17-mediated joint inflammation inmurine adjuVant-induced arthritis, "Clinical and Developmental Immunology, vol. 2013, Article ID 268065, 8 pages, 2013
14. N. C. Chavez-Tapia, N. Rosso, and C. Tiribelli,"Effect of intracellular lipid accumulation in a new model of non-Alcoholic fatty liver disease, "BMC Gastroenterology, vol. 12, article 20, 2012
15. U. Edvardsson, M. Bergstrm, M. Alexandersson, K. Bamberg, B. Ljung, and B. Dahllf,"Rosiglitazone (BRL49653), a PPAR-selective agonist, causes peroxisome proliferator-like liver effects in obese mice, "Journal of Lipid Research, vol. 40, no. 7, pp. 1177-1184, 1999
16. D. Cai, M. Yuan, D. F. Frantz et al.,"Local and systemic insulin resistance resulting from hepatic activation of IKK-And NF-B, "Nature Medicine, vol. 11, no. 2, pp. 183-190, 2005
17. M. Yuan, N. Konstantopoulos, J. Lee et al.,"Reversal of obesityand diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta, "Science, vol. 293, no. 5535, pp. 1673-1677, 2001
18. H. Tilg and A. M. Diehl,"Cytokines in alcoholic and nonalcoholic steatohepatitis, "The New England Journal ofMedicine, vol. 343, no. 20, pp. 1467-1467, 2000
19. S. K. Satapathy, S. Garg, R. Chauhan et al.,"Beneficial effects of tumor necrosis factor-inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis, "The American Journal of Gastroenterology, vol. 99, no. 10, pp. 1946-1952, 2004
20. J. W. Haukeland, J. K. Damas, Z. Konopski et al.,"Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2, "Journal of Hepatology, vol. 44, no. 6, pp. 1167-1174, 2006
21. J. M. Hui, A. Hodge, G. C. Farrell, J. G. Kench, A. Kriketos, and J. George,"Beyond insulin resistance in NASH: TNF-or adiponectin?"Hepatology, vol. 40, no. 1, pp. 46-54, 2004
22. J. Crespo, A. Cayoen, P. Fernendez-Gil et al.,"Gene expression of tumor necrosis factor and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients, "Hepatology, vol. 34, no. 6, pp. 1158-1163, 2001
23. L. A. Adams, C. O. Zein, P. Angulo, and K. D. Lindor,"A pilot trial of pentoxifylline in nonalcoholic steatohepatitis, "American Journal of Gastroenterology, vol. 99, no. 12, pp. 2365-2368, 2004
24. Z. Li, S. Yang, H. Lin et al.,"Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease, "Hepatology, vol. 37, no. 2, pp. 343-350, 2003
25. J. D. Browning and J. D. Horton,"Molecular mediators of hepatic steatosis and liver injury, "Journal of Clinical Investigation, vol. 114, no. 2, pp. 147-152, 2004
26. Y. Liu, J. Shi, J. Lu et al.,"Activation of peroxisome proliferatoractivated receptor-potentiates pro-inflammatory cytokine production, and adrenal and somatotropic changes of weaned pigs after Escherichia coli lipopolysaccharide challenge, "Innate Immunity, vol. 15, no. 3, pp. 169-178, 2009
27. R. Belfort, S. A. Harrison, K. Brown et al.,"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, "The New England Journal of Medicine, vol. 355, no. 22, pp. 2297-2307, 2006
28. C. W. Wu, E. S. H. Chu, C. N. Y. Lam et al.,"PPAR is essential for protection against nonalcoholic steatohepatitis, "GeneTherapy, vol. 17, no. 6, pp. 790-798, 2010
29. L. B. Van Wagner and M. E. Rinella,"The role of insulinsensitizing agents in the treatment of nonalcoholic steatohepatitis, "Therapeutic AdVances in Gastroenterology, vol. 4, no. 4, pp. 249-263, 2011
30. S. Liu, H.-J. Wu, Z.-Q. Zhang et al.,"The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats, "European Journal of Pharmacology, vol. 650, no. 1, pp. 384-389, 2011
31. V. Ratziu, P. Giral, S. Jacqueminet et al.,"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial, "Gastroenterology, vol. 135, no. 1, pp. 100-110, 2008
32. R. Barbuio, M. Milanski, M. B. Bertolo, M. J. Saad, and L. A. Velloso,"Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet, "Journal of Endocrinology, vol. 194, no. 3, pp. 539-550, 2007
33. V. T. Samuel, Z.-X. Liu, X. Qu et al.,"Mechanism of hepatic insulin resistance in non-Alcoholic fatty liver disease, "The Journal of Biological Chemistry, vol. 279, no. 31, pp. 32345-32353, 2004
34. K.-X. Gan, C. Wang, J.-H. Chen, C.-J. Zhu, and G.-Y. Song,"Mitofusin-2 ameliorates high-fat diet-induced insulin resistance in liver of rats, "World Journal of Gastroenterology, vol. 19, no. 10, pp. 1572-1581, 2013
35. J. C. Fraulob, R. Ogg-Diamantino, C. Fernandes-Santos, M. B. Aguila, and C. A. Mandarim-de-Lacerda,"A mouse model of metabolic syndrome: insulin resistance, fatty liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 mice fed a high fat diet, "Journal of Clinical Biochemistry and Nutrition, vol. 46, no. 3, pp. 212-223, 2010
36. B. Lam and Z. M. Younossi,"Review: treatment options for nonalcoholic fatty liver disease, "Therapeutic AdVances in Gastroenterology, vol. 3, no. 2, pp. 121-137, 2010
37. S. Bose and H. Kim,"Evaluation of in vitro anti-inflammatory activities and protective effect of fermented preparations of rhizoma atractylodis macrocephalae on intestinal barrier function against lipopolysaccharide insult, "Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 363076, 16 pages, 2013
38. L. Wang, X.-M. Qiu, Q. Hao, and D.-J. Li,"Anti-inflammatory effects of a Chinese herbal medicine in atherosclerosis via estrogen receptor mediating nitric oxide production and NFkB suppression in endothelial cells, "Cell Death and Disease, vol. 4, no. 3, p. e551, 2013
39. F. Tacke, T. Luedde, and C. Trautwein,"Inflammatory pathways in liver homeostasis and liver injury, "Clinical Reviews in Allergy and Immunology, vol. 36, no. 1, pp. 4-12, 2009
40. N. Ghosh, R. Ghosh, V. Mandal, and S. C. Mandal,"Recent adVances in herbal medicine for treatment of liver diseases, "Pharmaceutical Biology, vol. 49, no. 9, pp. 970-988, 2011
41. P. Zheng, G. Ji, Z. Ma et al.,"Therapeutic effect of puerarin on non-Alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways, "The American Journal of Chinese Medicine, vol. 37, no. 1, pp. 69-83, 2009
42. X. Chang, H. Yan, J. Fei et al.,"Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats, "Journal of Lipid Research, vol. 51, no. 9, pp. 2504-2515, 2010
43. C. Xiao, J. Li, X. Dong et al.,"Anti-oxidative and TNFalpha suppressive activities of puerarin derivative (4AC) in RAW264.7 cells and collagen-induced arthritic rats, "European Journal of Pharmacology, vol. 666, no. 1-3, pp. 242-250, 2011
44. P. Zheng, G. Ji, Z. Ma et al.,"Therapeutic effect of puerarin on non-Alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways, "The American Journal of Chinese Medicine, vol. 37, no. 1, pp. 69-83, 2009
45. M. J. Chung, N.-J. Sung, C.-S. Park et al.,"Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57 BL/6J mice, "European Journal of Pharmacology, vol. 578, no. 2-3, pp. 159-170, 2008
46. X. Xia, J. Yan, Y. Shen et al.,"Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis, "PLoS ONE, vol. 6, no. 2, Article ID e16556, 2011